孟鲁司特对过敏性紫癜患儿血浆细胞因子水平的疗效观察(1)
【摘要】 目的：研究探讨孟鲁司特对过敏性紫癜患儿血浆细胞因子水平的影响及其临床疗效。方法：选取本院收治的过敏性紫癜患儿100例作为研究对象，将其随机分为两组，每组各50例患者，对照组患儿给予抗组胺类药物、抗感染类药物以及钙剂、维生素C等常规的治疗药物，观察组患者在常规治疗的基础上给予孟鲁司特咀嚼片治疗。以两周为一个疗程，比较两组患者治疗前后的血浆细胞因子水平，观察其临床治疗效果。结果：观察组和对照组患者治疗前的IL-6、IL-8和TNF-α表达水平差异均无统计学意义(P>0.05)；治疗后，三项指标的表达水平都有显著降低，且与治疗前相比差异均有统计学意义(P<0.05)；观察组患者各项指标的下降程度超过对照组患者，两组比较差异具有统计意义(P<0.05)。观察组和对照组患者的临床治疗总有效率分别是96.0%和78.0%，两组比较差异有统计学意义(P<0.05)。结论：孟鲁司特治疗儿童过敏性紫癜具有临床疗效确切、安全性好的优点，可以对患儿血浆内的细胞因子进行调节，促进患儿免疫功能的改善，值得临床推广应用。
【关键词】 孟鲁司特； 过敏性紫癜； 血浆细胞因子； 临床疗效
, 百拇医药
【Abstract】 Objective：To study the clinical efficacy of montelukast in children with allergic purpura of plasma cytokine levels .Method： 100 children with allergic purpura were selected in our hospital as research subjects，and were randomly divided into two groups， the control group of children were given anti-histamine drugs， anti-infective drugs and calcium， vitamin C and other conventional drugs.The observation group was treated with montelukast chewable tablets treatment on the basis of conventional therapy. In two weeks for a course of treatment，the clinical effect of plasma cytokine levels in patients before and after treatment were compared and observed.Result： IL-6，IL-8 and TNF-α expression levels observed before the treatment，two groups of patients showed no significant difference(P>0.05)；after treatment， the expression levels of three indicators had decreased significantly，and compared with before the treatment， the differences were statistically significant(P<0.05)； observation group’ indicators decreased more than control group， the difference was statistically significant(P<0.05).Observation group and control group of patients with clinical response rates were respectively 96.0% and 78.0%， the difference was statistically significant(P<0.05).Conclusion：Montelukast treatment of children with allergic purpura have clinical efficacy， safety，and good benefits， cytokines can be adjusted within the plasma of children， promote the improvement of immune function in children， worthy of clinical application.
, 百拇医药
【Key words】 Montelukast； Purpura； Plasma cytokines； Clinical efficacy
过敏性紫癜是儿科临床的常见疾病，属于系统性血管炎的一种[1]。常规的过敏性紫癜的治疗主要以支持治疗为主，孟鲁司特作为一种选择性白细胞三烯受体拮抗剂，具有强大的抗炎活性，还能对外周血T细胞亚群数量进行调控[2]。本文就本院收治的过敏性紫癜患儿作为研究对象，探讨孟鲁司特对血浆细胞因子水平的影响及其临床应用价值，具体报告如下[3]。
1 资料与方法
1.1 一般资料 选取本院收治的过敏性紫癜患儿100例作为研究对象，所有患儿均符合美国风湿学会制定的相关诊断标准[4]。将其随机分为两组，每组各50例。观察组患儿中，男29例，女21例；年龄4～13岁，平均(7.9±1.7)岁；其中，单纯性过敏性紫癜患儿27例，合并关节症状的患儿9例，合并胃肠症状的患儿10例，合并肾脏症状的患儿4例；属于初次发病的患者有28例，多次反复发作的患者22例。对照组组患儿中，男28例，女22例；年龄5～14岁，平均(8.1±1.5)岁；其中，单纯性过敏性紫癜患儿29例，合并关节症状的患儿9例，合并胃肠症状的患儿9例，合并肾脏症状的患儿3例；属于初次发病的患者有30例，多次反复发作的患者20例。两组年龄、性别、患病情况等一般资料比较差异均无统计学意义(P>0.05)，具有可比性。, 百拇医药(刘芳等)
【关键词】 孟鲁司特； 过敏性紫癜； 血浆细胞因子； 临床疗效
, 百拇医药
【Abstract】 Objective：To study the clinical efficacy of montelukast in children with allergic purpura of plasma cytokine levels .Method： 100 children with allergic purpura were selected in our hospital as research subjects，and were randomly divided into two groups， the control group of children were given anti-histamine drugs， anti-infective drugs and calcium， vitamin C and other conventional drugs.The observation group was treated with montelukast chewable tablets treatment on the basis of conventional therapy. In two weeks for a course of treatment，the clinical effect of plasma cytokine levels in patients before and after treatment were compared and observed.Result： IL-6，IL-8 and TNF-α expression levels observed before the treatment，two groups of patients showed no significant difference(P>0.05)；after treatment， the expression levels of three indicators had decreased significantly，and compared with before the treatment， the differences were statistically significant(P<0.05)； observation group’ indicators decreased more than control group， the difference was statistically significant(P<0.05).Observation group and control group of patients with clinical response rates were respectively 96.0% and 78.0%， the difference was statistically significant(P<0.05).Conclusion：Montelukast treatment of children with allergic purpura have clinical efficacy， safety，and good benefits， cytokines can be adjusted within the plasma of children， promote the improvement of immune function in children， worthy of clinical application.
, 百拇医药
【Key words】 Montelukast； Purpura； Plasma cytokines； Clinical efficacy
过敏性紫癜是儿科临床的常见疾病，属于系统性血管炎的一种[1]。常规的过敏性紫癜的治疗主要以支持治疗为主，孟鲁司特作为一种选择性白细胞三烯受体拮抗剂，具有强大的抗炎活性，还能对外周血T细胞亚群数量进行调控[2]。本文就本院收治的过敏性紫癜患儿作为研究对象，探讨孟鲁司特对血浆细胞因子水平的影响及其临床应用价值，具体报告如下[3]。
1 资料与方法
1.1 一般资料 选取本院收治的过敏性紫癜患儿100例作为研究对象，所有患儿均符合美国风湿学会制定的相关诊断标准[4]。将其随机分为两组，每组各50例。观察组患儿中，男29例，女21例；年龄4～13岁，平均(7.9±1.7)岁；其中，单纯性过敏性紫癜患儿27例，合并关节症状的患儿9例，合并胃肠症状的患儿10例，合并肾脏症状的患儿4例；属于初次发病的患者有28例，多次反复发作的患者22例。对照组组患儿中，男28例，女22例；年龄5～14岁，平均(8.1±1.5)岁；其中，单纯性过敏性紫癜患儿29例，合并关节症状的患儿9例，合并胃肠症状的患儿9例，合并肾脏症状的患儿3例；属于初次发病的患者有30例，多次反复发作的患者20例。两组年龄、性别、患病情况等一般资料比较差异均无统计学意义(P>0.05)，具有可比性。, 百拇医药(刘芳等)